膀胱癌患者外周血循环肿瘤细胞中Survivin的表达

严勇; 孙洵; 李岗; 郑昕; 马绍翔; 李勇; 赵润恒; 王珂

膀胱癌患者外周血循环肿瘤细胞中Survivin的表达

昆明市第一人民医院昆明医科大学附属甘美医院泌尿外科

基金项目:

基金：昆明市科技局科研基金资助项目 (2015-2-S-01577);

计量
- 文章访问数: 2403
- HTML全文浏览量: 849
- PDF下载量: 75
- 被引次数: 0
出版历程
- 收稿日期: 2017-04-19

Expression of Survivin in Circulating Tumor Cells in Patients with Bladder Cancer

Funds:

基金：昆明市科技局科研基金资助项目 (2015-2-S-01577);

摘要

摘要: 目的探讨循环肿瘤细胞 (CTC) 中Survivin的表达情况, 并探讨其与膀胱癌患者病理分期、分级之间的相关性.方法采集50例膀胱癌患者外周静脉血, 应用Can Patrol技术检测出不同型别CTC, 用免疫组化法检测其中的Survivin表达, 分析CTC中Survivin的表达与膀胱癌患者病理分期、分级之间的相关性.结果 50例膀胱癌CTC阳性率为42% (21/50) , 间质型CTCSurvivin阳性率最高, 差异有统计学意义 (P<0.05) ;膀胱癌CTC及Survivin阳性率与肿瘤大小、数目、病理分期以及病理分级有关 (P<0.05) ;多因素Logistic回归分析显示, CTC及Survivin阳性率与肿瘤大小、病理分期和病理分级有关 (P<0.05) .结论间质型CTCSurvivin阳性表达率最高, CTC及其中的Survivin与膀胱癌患者肿瘤大小、病理分期及分级相关.
- 膀胱肿瘤 /
- 循环肿瘤细胞 /
- Survivin
Abstract: Objective To investigate the expression of Survivin in circulating tumor cells (CTC) and the association between CTC and clinicopathologic characteristics of bladder cancer. Methods Clinically confirmed 50 bladder cancer patients were enrolled in the study. Can Patrol technology was applied to determine different types of CTC. And expressions of Survivin in these CTC were detected by immunohistochemical procedures. C2 test and multi-variates Logistic regression were employed to determine the association between Survivin in CTC and clinicopathologic characteristics of tumors. Results The positive rate of CTC in bladder cancer was 42% (21/50) .The mesenchymal type CTC had the most expression of Survivin (90.9%, with P<0.05) . The presence of CTC and positive expression of Survivin were correlated with tumor size, number of tumor, pathological stage, and pathological grade (P<0.05) . Multivariate analysis confirmed that the presences of CTC and positive expression of Survivin were significant correlated with tumor size, pathological stage, and pathological grade (P <0.05) .Conclusion The presence of CTC and expression of Survivin may suggest the re-occurrence, progression and metastasis of bladder tumor.
- Bladder neoplasms /
- Circulating tumor cells /
- Survivin

HTML全文

参考文献(25)

[1]	[1]ZENG H, ZHENG R, GUO Y, et al.Cancer survival in China, 2003-2005:A population-based study[J].Int J Cancer, 2015, 136 (8) :1921-1930.
[2]	[2]TORRE L A, BRAY F, SIEGEL R L, et al.Global cancer statistics, 2012[J].CA Cancer J Clin, 2015, 65 (2) :87-108.
[3]	[3]RINK M, CHUN F K, DAHLEM R, et al.Prognostic role and HER 2expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy:A prospective study[J].Eur Urol, 2012, 61 (4) :810-817.
[4]	[4]VOLKMER B G, KUEFER R, BARTSCH G C, et al.Oncological followup after radical cystectomy for bladder cancer is there any benefit[J].J Urol, 2009, 181 (4) :1587-1593.
[5]	[5]TURKER I, UYETURK U, SONMEZ O U, et al.Detection of circulating tumor cells in breast cancer patients:prognostic predictive role[J].Asian Pac J Cancer Prev, 2013, 14 (3) :1601-1607.
[6]	[6] DU Y J, LI J, ZHU W F, et al.Survivin m RNA-circulating tumor cells Predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients[J].Tumour Biol, 2014, 35 (5) :4499-4507.
[7]	[7] HU B, ROCHEFORT H, GOLDKOM A.Circulating tumor cells in prostate cancer[J].Cancers (Basel) , 2013, 5 (4) :1676-1690.
[8]	[8]KANIA J, KONTMK S J, MARLICZ K, et al.Expression of survivin and caspase-3 in gastric cancer[J].Dig Dis Sci, 2003, 48 (2) :266-271.
[9]	[9]SAUTER G, ALGABA F, AMIN M, et al.Tumour of urinary system:non-invasive urothelial neoplasia[M]In Eble JN, Sauter G, Epstein JI, Sesterhenn, eds.WHO Classification of Tumour of urinary system and male genital organs.Lyon:IARCC Press, 2004:29-34.
[10]	[10]NEZOS A, PISSIMISIS N, LEMBESSIS P, et al.Detection of circulating tumor cells in bladder cancer patients[J].Cancer Treat Rev, 2009, 35 (3) :272-279.
[11]刘侃, 张俊哲.基于微流控芯片的循环肿瘤细胞的分离、检测技术[J].电脑知识与技术, 2014, 10 (9) :2093-2097.
[12]	[12]HONG B, ZU Y.Detecting circulating tumor cells:current challenges and new trends[J].Theranostics, 2013, 3 (6) :377-394.
[13]	[13]PARKINSON D R, DRACOPOLI N, PETTY B G, et al.Considerations in the development of circulating tumor cell technology for clinical use[J].J Transl Med, 2012, 10 (1) :138-157.
[14]	[14]BEDNARZ-KNOLL N, ALIX-PANABI6RES C, PANTEL K.Plasticity of disseminating cancer cells in patients with epithelial malignancies[J].Cancer Metastasis Rev, 2012, 31 (3) :673-687.
[15]	[15]MIN Y, ADITYA B, BEN S, et al.Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition[J].Science, 2013, 339 (6119) :580-584.
[16]	[16]DU Y J, LI J, ZHU W F, et al.Survivin m RNA-circulating tumor cells Predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients[J].Tumour Biol, 2014, 35 (5) :4499-4507.
[17]	[17]MikulováV, CabiňakováM, JanatkováI, et a1.Detection of circulating tumor cells during follow-up of patients with early breast cancer:clinical utility for monitoring of therapy efficacy[J].Scand J Clin Lab Invest, 2014, 74 (2) :132-142.
[18]	[18]JUDONG YANG, MICHAEL B, CAMPION, et al.Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma[J].Hepatology, 2016, 1 (63) :148-158.
[19]	[19]HU B, ROCHEFORT H, GOLDKOM A.Circulating tumor cells in prostate cancer[J].Cancers (Basel) , 2013, 5 (4) :1676-1690.
[20]	[20]KEE-THAI K, THOMAS H, HSIAO-YEN H, et al.Expression of survivin in bladder cancer cell lines using quantitative real-time polymerase chain reaction[J].Urol Sci, 2013, 15 (2) :2348-2350.
[21]	[21]LEHNER R, LUCIA M S, JARBOE E A, et al.Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma[J].Appl Immunohistochem Mol Morphol, 2002, 10 (2) :134-138.
[22]	[22]PLAKS V, KOOPMAN C D, WERB Z.Cancer.Circulating tumor cells[J].Science, 2013, 341 (6151) :1186-1188.
[23]	[23]GAZZANIGA P, GRADILONE A, DE B E, et al.Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer:a Cell Search analysis[J].Annals of Oncology, 2012, 23 (1) :2352-2356.
[24]	[24]GRADILONE A, PETRACCA A, NICOLAZZO C, et al.Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer[J].Bju International, 2010, 106 (5) :710-715.
[25]	[25]SHIYANG W U, ZHIMING L I U, SUYAN LI U, et al.Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions[J].Clin Chem Lab Med, 2014, 52 (23) :243-251.

相关文章(20)

[1]	齐潇, 钟兆铭, 孙传政. 肿瘤相关中性粒细胞与肿瘤发生发展的研究进展, 昆明医科大学学报.
[2]	李珲, 平秦榕, 史云强, 王春晖, 杨洋, 胡礼炳, 毕晓方, 李健, 钟一鸣. 外周血CTCs与前列腺癌临床特征的相关性, 昆明医科大学学报.
[3]	黄宇, 栾婷, 王海峰, 王剑松. 液体活检在监测膀胱癌转移及疗效分析中的研究进展, 昆明医科大学学报.
[4]	张建华, 申正超, 陈印, 顾鹏, 赵晖, 申吉泓, 柯坤彬. 铥激光治疗合并尿道狭窄的非肌层浸润性膀胱肿瘤, 昆明医科大学学报.
[5]	冉震, 朱云莎, 海冰, 张劲松. 肿瘤组织内肿瘤浸润淋巴细胞和前列腺癌术后复发的关系, 昆明医科大学学报.
[6]	虎住飞, 何永文. 热诱导肿瘤细胞凋亡的机制研究进展, 昆明医科大学学报.
[7]	解燕华. CIK细胞治疗恶性肿瘤患者的护理体会, 昆明医科大学学报.
[8]	张劲松. 根治性膀胱癌标本中肿瘤侵犯前列腺及精囊的病理学研究, 昆明医科大学学报.
[9]	詹辉. CD3+T淋巴细胞在膀胱癌肿瘤上皮与癌旁尿路上皮中的分布差异研究, 昆明医科大学学报.
[10]	孙志敏. 增殖细胞核抗原在头颈部肿瘤中的应用进展, 昆明医科大学学报.
[11]	胡礼炳. 云南睾丸生殖细胞肿瘤105例临床特点与疗效评价, 昆明医科大学学报.
[12]	孙志敏. 增殖细胞核抗原在头颈部肿瘤中的应用进展, 昆明医科大学学报.
[13]	李瑞. CIK细胞治疗泌尿系统恶性肿瘤的护理体会, 昆明医科大学学报.
[14]	魏向群. 早期宫颈癌患者术前外周血CK19 mRNA的检测及其临床意义, 昆明医科大学学报.
[15]	马真. 改良型TAT-VP3融合蛋白对膀胱癌BIU-87细胞Bcl-2和Survivin表达的影响, 昆明医科大学学报.
[16]	艾毅钦. 87例直肠腺癌患者肿瘤分期和细胞免疫状态分析, 昆明医科大学学报.
[17]	. 恶性胸水培养肿瘤细胞失败原因分析, 昆明医科大学学报.
[18]	李昆仑. RNAi抑制Survivin基因的表达对乳腺癌SKBr-3细胞的影响, 昆明医科大学学报.
[19]	. 抗凋亡基因Survivin在分化型甲状腺癌中的表达及临床意义, 昆明医科大学学报.
[20]	. 宫颈癌组织中Ki-67及Survivin的表达及其相关性研究, 昆明医科大学学报.